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V olumetric modulated arc therapy (VMAT) is a highly conformal intensity-modulated radiation 
technique that is widely used for the treatment of pros-
tate,  cervical,  head and neck,  and many other cancers 
[1-6].  Compared to intensity-modulated radiation 
therapy (IMRT),  VMAT can achieve comparable clini-
cal outcomes in a shorter treatment time [7 , 8].  The 
feasibility and benefits of VMAT for the treatment of 
esophageal cancer were recently reported [9-11].  
VMAT can deliver concentrated doses to planning tar-
get volumes (PTVs) and reduced doses to the heart 
without significantly increasing the dose to the normal 
lungs.  Although some investigators have compared the 
efficacy of IMRT and VMAT to that of three-dimen-
sional conformal radiotherapy (3D-CRT) [9-11],  the 
definition of PTV in their reports was based on the 
involved field irradiation (IFI).  There are also twosome 
reports indicating the efficacy of three-field regional 
lymph node dissection in esophageal cancer [12 , 13].  
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We investigated the feasibility of simultaneous integrated boost (SIB) volumetric modulated arc therapy 
(VMAT) using elective nodal irradiation (ENI) for middle or lower esophageal cancer and compared it with 
three-dimensional conformal radiotherapy (3D-CRT).  The study included 15 patients.  The prescribed doses 
included a standard dose (50.4 Gy) and a high dose (60 Gy) for the planning target volume (PTV) of the 
involved lesions.  The objective of the whole lung volume receiving ≥ 20 Gy (V20Gy) was < 30%,  and the mean 
lung dose (MLD) was < 20 Gy.  The volumes of the lung receiving 5 Gy (V5Gy) and the heart receiving 30-50 Gy 
(V30-50Gy) were kept as low as reasonably achievable.  As a result,  SIB-VMAT showed superior dose conformity 
for the PTV (p< 0.001).  Although the lung V5Gy was significantly increased (p< 0.001),  the V20Gy and MLD 
showed no significant increase.  The heart V30-50Gy showed a > 20% reduction in the mean against 3D-CRTs.  Our 
results demonstrate the feasibility of SIB-VMAT for the treatment of middle or lower esophageal cancer with 
ENI.  Although attention should be paid to the low-dose area of the lungs,  SIB-VMAT would be a promising 
treatment option with improved outcomes for esophageal cancer.
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The benefits of large-field elective nodal irradiation 
(ENI) in chemoradiotherapy for thoracic esophageal 
cancer are controversial [14 , 15].  However,  in accor-
dance with the concept of three-field regional lymph 
node dissection in curative surgery,  ENI has been 
widely used in Japanese institutions,  and its efficacy has 
been reported [16-18].
The problems with using ENI for middle or lower 
thoracic esophageal cancer are that (1) the high dose 
area is very close to the heart,  and (2) the elective nodal 
area covers the whole lung level.  Severe radiation pneu-
monitis (RP) and long-term toxicity of the heart are 
significant problems encountered during the treatment 
of esophageal cancer [14].  We thus considered that it 
would be useful to evaluate the feasibility of VMAT 
with ENI.  There are no previous reports comparing 
VMAT with ENI and 3D-CRT with ENI for middle or 
lower thoracic esophageal cancer.
In addition,  the outcomes of chemoradiotherapy in 
esophageal cancer are still rather dismal,  with a poor 
prognosis generally related to locoregional failure [19-
21].  One of the ways to improve the local control rate 
would be a dose escalation to the involved area [22 , 23].  
A recent study reported a favorable outcome using 
high-dose (≥ 60 Gy) IMRT [24].  Simultaneous inte-
grated boost (SIB) VMAT can easily achieve the dose 
escalation to the involved tumors without changing the 
dose to the elective nodal area [25-27].  Therefore,  we 
conducted the present study to evaluate whether SIB-
VMAT with ENI is feasible for middle or lower thoracic 
esophageal cancer,  and we compared this combination 
with 3D-CRT at a standard dose (50.4 Gy) and a high 
dose (60 Gy).
Patients and Methods
This study was approved by our institutional Ethics 
Committee (No. 692).  Informed consent to participate 
was obtained from all of the patients.  This was a plan-
ning study,  and we created and compared two 
plans: one using SIB-VMAT and the other using 
3D-CRT with the computed tomography (CT) data 
from the same patients.
Patient characteristics and details of the initial 
therapy. CT data from 15 patients diagnosed with 
squamous cell carcinoma of the middle or lower tho-
racic esophagus were used in this study.  All of the 
patients had received radiation therapy in our institu-
tion by 3D-CRT,  IMRT,  or VMAT during the period 
from June 2015 to October 2017.  We started using IMRT 
and VMAT in December 2016,  and thereafter we treated 
essentially all patients with esophageal cancer with 
VMAT.  Patients with pacemakers were an exception;  
VMAT was not indicated in these cases due to the low- 
dose irradiation to the pacemaker.  The primary lesions 
involved the middle thoracic esophagus (7 patients),  
lower thoracic esophagus (3 patients),  and middle plus 
lower thoracic esophagus (5 patients) (Table 1).
CT scans for the plan and linear accelerator. All 
patients underwent CT-based planning.  The CT was 
performed in the treatment position using a helical 
scanner.  For each patient,  3-mm-thick images for 
3D-CRT and 2-mm-thick images for VMAT were 
obtained.  All plans were developed using the Elekta 
Synergy linear accelerator with an Agility multileaf 
(160 leaves) collimator (MLC) (Elekta,  Stockholm,  
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????? ?　 Characteristics and treatment details of the 15 patients 
with squamous cell carcinoma
????????
Age,  years; median (range) 77 (58-86)
Male 14
Female  1
Primary site:
Mｔ  7
MtLt  4
Lt  3
LtMt  1
Clinical stage＊
I  8
II  4
III  3
??????????????????
Radiation therapy alone  9
Chemoradiotherapy  6
Cumulative dose,  Gy; median (range) 60 (50.4-66)
Radiation technique,  initial treatment:
3D-CRT  9
Initial ﬁeld: 3D-CRT,  boost ﬁeld: VMAT  1
IMRT  2
VMAT  3
＊Japanese classiﬁcation of esophageal cancer,  11th edition.  
3D-CRT,  three-dimensional conformal radiotherapy; IMRT,  intensi-
ty-modulated radiation therapy; LtMt,  middle and lower thoracic 
esophagus (main lesion exist at Lt); Mt,  middle thoracic esopha-
gus; Lt,  lower thoracic esophagus; MtLt,  middle and lower tho-
racic esophagus (main lesion exist at Mt); VMAT,  volumetric 
modulated arc therapy.
Sweden) with a leaf width of 5 mm.
Pretreatment evaluation,  targets,  and organs at 
risk (OARs). The pretreatment evaluation included 
endoscopy and CT of the esophagus.  The extent of the 
gross tumor volume at the primary site (GTVp) was 
determined by endoscopy and CT.  The gross tumor 
volume of the lymph nodes (GTVn) was defined using 
CT when the nodes were ≥ 1 cm in their shortest axis.  
The clinical target volume of the primary site (CTVp) 
was delineated with 2-2.5 cm superior-inferior margins 
and 0.5 cm lateral and anterior-posterior margins for 
the GTVp.  The clinical target volume of the involved 
lymph node (CTVn) was delineated with 0.3 cm uni-
form margins for the GTVn.
The clinical target volume for ENI (CTVe) was 
defined as follows: regardless of the subsite of the pri-
mary tumor,  the lower cervical,  peri-esophageal,  
mediastinal,  and perigastric nodes were included in the 
elective nodal area.  Celiac nodes were also included 
when the lower esophagus was involved.  “CTV1” con-
sisted of the CTVp,  CTVn,  and CTVe.  “CTV2” con-
sisted of the CTVp and CTVn.  The planning target 
volume (PTV) was defined as CTV plus a 1-1.5 cm 
margin in the craniocaudal direction and a 0.5-1 cm 
margin in the lateral direction to account for respiratory 
organ motion and daily setup errors.
An example of a PTV is shown in Fig. 1.  Normal 
tissue organs included both of the lungs (as a single 
organ),  the heart,  spinal cord (including the spinal 
canal),  both of the kidneys (as a single organ),  liver,  
and stomach.  The heart was contoured according to the 
Radiation Therapy Oncology Group (RTOG) contour-
ing atlases for OARs in Thoracic Radiation Therapy 
(https://www.rtog.org/LinkClick.aspx?fileticket= 
qlz0qMZXfQs%3d&tabid=361,  accessed July 19,  2018),  
and the pericardium was defined as the sac-like struc-
ture (thickness: 5 mm) at the surface of the heart 
[28 , 29].  The PTV was not subtracted from the volumes 
of the OARs when calculating the dose-volume histo-
gram (DVH).
3D-CRT planning. Treatment plans for 3D-CRT 
were generated by the Pinnacle ver.  9.6 treatment plan-
ning system (Philips Medical Systems,  Andover,  MA,  
USA).  Tissue heterogeneity corrections were applied to 
all dose calculations.  We used a 3D convolution/super-
position algorithm that is considered an accurate 
dose-calculation method apart from the Monte Carlo 
simulation for dose calculations.  A 10-MV beam was 
used in all of the 3D-CRT plans.  The dose calculation 
grid size was 2-mm in all cases.
The prescribed dose was 41.4 Gy (in 23 fractions of 
1.8 Gy/fraction) to the PTV1 in the standard-dose plan 
and 40 Gy (in 20 fractions of 2 Gy/fraction) to the 
PTV1 in the high-dose plan.  Radiation to the PTV1 
was delivered using the four-field technique in the stan-
dard-dose plan,  and using the anterior-posterior 
opposed fields in the high-dose plan as described previ-
ously [16 , 17].  A booster dose of 9 Gy (in 5 fractions of 
1.8 Gy/fraction) in the standard-dose plan and 20 Gy 
(in 10 fractions of 2 Gy/fraction) in the high-dose plan 
was administered to the PTV2 using oblique fields to 
avoid the spinal cord.  The treatment portal covered the 
PTV plus a 0.5-0.7 cm margin to account for the pen-
umbra.  The field-in-field technique was used to 
improve the dose distribution of the PTV if needed.  
The normalization point was set to the isocenter or a 
proper reference point to cover the PTV.
VMAT planning. Treatment plans for SIB-
VMAT were generated by the Monaco ver.  5.11 treat-
ment planning system (Elekta).  Tissue heterogeneity 
corrections were applied to all dose calculations.  A 
6-MV beam was used in all of the SIB-VMAT plans as 
described previously [9-11].  The X-ray voxel Monte 
Carlo (XVMC) algorithm was used for dose calcula-
tions.  The dose calculation grid size and the statistical 
uncertainty of the calculation were set to 2 mm and 1% 
per plan,  respectively.  A double-arc with an avoidance 
sector plan was generated in this study.
The VMAT had gantry angles of 135°-180°,  180°-225°,  
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Anterior-posterior view Lateral view
???? ?　 Anterior-posterior and lateral views of a sample planning 
target volume (PTV).  Blue: The PTV1 (elective nodal area).  
Red: The PTV2 (involved lesion).  Pink: heart.  The heart is adja-
cent to the PTV2 in middle or lower esophageal cancer.
and 330°-30° (Fig. 2),  which were chosen based on pre-
vious reports [9 , 30].  The collimator angle was set at 0° 
in all of the plans.  The prescribed doses were 45 Gy to 
the PTV1 in both the standard-dose plan (in 28 frac-
tions) and high-dose plan (in 30 fractions).  A total dose 
of 50.4 Gy in the standard-dose plan (in 28 fractions) 
and 60 Gy in the high-dose plan (in 30 fractions) was 
prescribed to the PTV2.
Planning objectives of VMAT. We normalized 
each SIB-VMAT plan so that 100% of the prescribed 
dose was delivered to 50% of the PTV2.  The planning 
objectives for the PTV1 and PTV2 were ≥ 95% of the 
target volume receiving ≥ 95% but no more than 107% 
of the prescribed dose of < 1% of the target volume as 
reported by Nicolini [9].  The whole lung volume 
receiving ≥ 20 Gy (V20Gy) was < 0%,  and the mean lung 
dose (MLD) was < 20 Gy [31].  The volume receiving 
≥ 5 Gy (V5Gy) was kept as low as reasonably achievable.
In all of the plans,  the volume of the heart receiving 
30-50 Gy (V30-50Gy) was kept as low as reasonably achiev-
able.  The maximum dose limit for the spinal cord was 
46 Gy.  The mean dose constraints for the kidney and 
liver doses were < 15 Gy and < 30 Gy,  respectively.
Parameters analyzed. The quantitative evalua-
tion of the plan was performed using the standard 
dose-volume histogram (DVH).  For the PTV,  the D98%,  
D95%,  D5%,  and D2% (dose received by 98%,  95%,  5%,  
and 2% of the volume) values are reported.  The homo-
geneity index (HI) is expressed in terms of D5%-D95% 
(the difference between the dose covering 5% and 95% 
of the PTV).
The degree of conformity of the plan was measured 
using the RTOG conformity index (RCI) and the 
Paddick conformity index (PCI).  The formula for the 
PCI [32] is: (TVPIV)2/(TV×PIV),  in which TV is the 
target volume and PIV is the prescription isodose vol-
ume.  TVPIV is target volume covered by PIV.  The for-
mula for the RCI [33] is: PIV/TV.  An RCI value of 1.0 
indicates ideal conformity,  and a value > 1.0 or < 1.0 
indicates over- or under-coverage,  respectively.  A PCI 
value of 1.0 indicates ideal conformity,  but a value < 1.0 
is due to both over- and under-coverage of the PTV.  For 
the OARs,  the analysis included the mean dose and the 
set of appropriate Vx (Gy) values.
Follow-up after the initial therapy. After the ini-
tial therapy,  CT and endoscopy were performed every 
1-3 months in the first year,  and every 3-6 months in 
the second year.  For the assessment of toxicity,  the 
Common Terminology Criteria for Adverse Events 
(CTCAE) ver.  4.0 was adopted.  On the basis of the 
onset time,  late toxicities were those that were detected 
6 months after the start of the treatment.
Statistical analysis. To compare the two different 
plans for each patient,  we used Student’s paired t-test 
(when the data showed a normal distribution) or the 
paired Wilcoxon signed-rank test (when the data 
showed a non-normal distribution).  P-values < 0.05 
were considered significant.  The mean value of the dif-
ference (3D-CRT minus VMAT) and the 95% confi-
dence interval (CI) for the difference in parameters 
between each plan was calculated.  Statistical analyses 
were performed using the JMP v.10.0 software (SAS 
Institute,  Cary,  NC,  USA).
Results
Tables 2 and 3 summarize the descriptive statistics of 
the 3D-CRT and VMAT for the standard- and high-
dose plans.  VMAT significantly improved the confor-
mity index compared to 3D-CRT.  In the heart and 
pericardium,  VMAT realized a significantly lower value 
for all parameters (all p-values were < 0.001).  A > 20% 
reduction of V30-50Gy was confirmed in the heart.  In the 
lung,  VMAT showed a significantly higher V5Gy in both 
the standard- and high-dose plans (p < 0.001).  VMAT 
showed no significant difference in the V20Gy for the 
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180°-225°
0
90270
330°-30°
135°-180°180
???? ?　 The arc arrangement of a double-arc with avoidance sec-
tor.  The VMAT consisted of gantry angles of 135℉-180℉, 180℉-225℉, 
and 330℉-30℉.
standard-dose plan (p = 0.35) but showed a significantly 
lower V20Gy for the high-dose plan (p = 0.004).  Other 
parameters showed no significant differences in the 
lungs.  The results of the DVH analysis for other OARs 
(showing slight differences) are provided in Tables 2 
and 3.
The median follow-up time was 16 months after the 
initial therapy.  The incidence of late toxicities including 
pneumonitis and pericardial effusion of grade 2 or 
more is shown in Table 4.  There was one grade 4 peri-
cardial effusion,  and the patient needed pericardial 
drainage and fenestration at 27 months after treatment.
Discussion
We compared SIB-VMAT and 3D-CRT for middle 
and lower esophageal cancers using ENI at doses of 
50.4 Gy and 60 Gy.  The results demonstrated that SIB-
VMAT could generate plans with superior dose confor-
mity for the target volume and with a significant reduc-
tion in doses for the heart and pericardium without 
worsening the major parameters of the lung (V20Gy and 
????????? ???? ????????????????????????????????????????? ???
????? ?　 Summary of the DVH analysis for the standard-dose plan: comparison between 3D-CRT and VMAT
Parameter 50.4 Gy
3D-CRT
Median (range)
VMAT
Median (range) Mean of (3D-CRT-VMAT)
3D-CRT vs. VMAT
(95% CI) P value
PTV2 (301±81 ml)
D2% (Gy) 52 (51-53.9) 52.2 (51.9-52.5) －0.1 (－0.4 to 0.3) 0.777⁂
D5% (Gy) 51.8 (50.9-53.2) 51.8 (51.5-52.1) 0.1 (－0.2 to 0.4) 0.603⁂
D95% (Gy) 48.5 (45.2-49.8) 48.8 (48.1-49.3) －0.5 (－1.1 to 0.1) 0.112⁂
D98% (Gy) 47.7 (41.6-49.2) 48.4 (47.5-49) ND ND 0.043‡
D5%-D95% (Gy) 3.4 (1.9-6.4) 3 (2.3-3.9) 0.6 (0.1 to 1.1) 0.026⁂
RCI 3.13 (1.99-4.81) 2.03 (1.52-2.82) 1.12 (0.78 to 1.45) <0.001⁂
PCI 0.3 (0.21-0.41) 0.49 (0.35-0.61) －0.18 (－0.22 to －0.15) <0.001⁂
Lungs (3338±943 ml)
Mean (Gy) 12.6 (9.3-14.8) 12.7 (10.5-14.8) －0.6 (－1.2 to 0.1) 0.072⁂
V5Gy (%) 56.4 (42.8-62) 60.6 (47.4-70.9) －6.9 (－9.9 to －3.9) <0.001⁂
V10Gy (%) 42.7 (30-48) 37.3 (29.8-48.4) 0.9 (－2.2 to 3.9) 0.54⁂
V20Gy (%) 22.2 (17.5-34.7) 22.9 (16.6-27.8) 1.2 (－1.5 to 3.9) 0.35⁂
Heart (612±173 ml)
Mean (Gy) 37 (27.2-45.8) 29 (24-34.1) 7.3 (5.8 to 8.9) <0.001⁂
V30Gy (%) 78.4 (54.6-93.4) 41.7 (30.9-61.4) 33.4 (29.3 to 37.4) <0.001⁂
V40Gy (%) 46.8 (22.9-75.7) 18.9 (10.5-35.8) 26.8 (21.4 to 32.2) <0.001⁂
V50Gy (%) 25.6 (6.4-56.3) 1.1 (0.4-3.7) 22.2 (15.5 to 29) <0.001⁂
Pericardium (179±27 ml)
Mean (Gy) 30.5 (23.8-38.7) 26.8 (21.3-33.3) 3.4 (2.7 to 4.2) <0.001⁂
V30Gy (%) 59.7 (41.6-76.6) 38.8 (26.5-55) 18.7 (17 to 20.4) <0.001⁂
V40Gy (%) 36.8 (22.4-55) 26.8 (15.5-42.3) 9.9 (6.7 to 13.1) <0.001⁂
V50Gy (%) 17.6 (9.8-29.9) 8.2 (4.9-14.6) ND ND <0.001‡
Liver (1074±219 ml)
Mean (Gy) 9.5 (5.2-15.1) 8.9 (4.2-14.9) 0.3 (－0.1 to 0.7) 0.155⁂
V30Gy (%) 13.6 (6-24.5) 13.7 (3.8-25.3) －0.4 (－1.5 to 0.7) 0.484⁂
Kidneys (254±52 ml)
Mean (Gy) 3.6 (0.6-12.3) 4.3 (0.4-6.1) 0.7 (－0.3 to 1.8) 0.169⁂
Spinal cord (57±14 ml)
Max (Gy) 44 (42.9-45) 41 (39.3-42.7) 2.9 (2.3 to 3.5) <0.001⁂
Stomach (180±60 ml)
Mean (Gy) 30.1 (10.1-39.1) 31.6 (10.2-37.7) －0.4 (－1.1 to 0.3) 0.233⁂
DVH,  dose-volume histogram; 3D-CRT,  three-dimensional conformal radiotherapy; VMAT,  volumetric modulated arc therapy; CI,  conﬁ-
dence interval; PTV,  planning target volume; Dx%,  dose received>x% of volume; VxGy,  volume receiving>x Gy; RCI; RTOG confor-
mity index; PCI,  Paddick conformity index; ND,  Not Determined.
⁂ Studentʼs paired t-test,  ‡ Wilcoxon signed-rank test
MLD).  Although attention should be paid to the 
increase in the low-dose area (V5Gy) of the lungs,  the 
results of this study could provide great value in clinical 
settings.
In thoracic radiotherapy for esophageal and lung 
cancers,  the relationships between the heart/pericar-
dium dose and the outcomes or adverse events have 
been reported.  Fukada et al.  [34] reported that pericar-
dium V45Gy ≥ 58% and its mean dose of ≥ 36.5 Gy are risk 
factors for symptomatic pericardial effusion (SPE).  
Ogino et al.  [28] showed that pericardium V50Gy ≥ 17% 
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????? ?　 Summary of the DVH analysis for the high-dose plan: Comparison between 3D-CRT and VMAT
Parameter 60 Gy
3D-CRT
median (range)
VMAT
median (range) mean of (3D-CRT-VMAT)
3D-CRT vs. VMAT
(95% CI) P value
PTV2 (301±81 ml)
D2% (Gy) 62 (60.2-64.4) 63 (62.6-63.6) －1.2 (－1.8 to －0.6) <0.001⁂
D5% (Gy) 61.7 (60-63.5) 62.5 (62.1-62.9) －0.9 (－1.5 to －0.4) 0.0014⁂
D95% (Gy) 57.6 (52.4-58.9) 57.3 (57-58) ND ND 0.903‡
D98% (Gy) 56.1 (48.2-58) 56.4 (56-57.6) ND ND 0.351‡
D5%-D95% (Gy) 4.2 (2.2-8.6) 5.3 (4-5.7) ND ND 0.048‡
RCI 2.8 (1.78-4.45) 1.28 (1.18-1.59) ND ND <0.001‡
PCI 0.33 (0.22-0.45) 0.74 (0.62-0.8) －0.4 (－0.43 to －0.37) <0.001⁂
Lungs (3338±943 ml)
Mean (Gy) 14 (10.2-16) 13.3 (10.6-16.9) －0.1 (－0.9 to 0.6) 0.667⁂
V5Gy (%) 56.3 (42-62.4) 63.1 (54.2-72.3) －9.3 (－12.2 to －6.4) <0.001⁂
V10Gy (%) 40.3 (27.4-47.9) 39.4 (30.2-51.8) －1.7 (－5.1 to 1.8) 0.31⁂
V20Gy (%) 28.2 (19.3-33.2) 22.2 (13.8-30.4) 4.5 (1.7 to 7.3) 0.004⁂
Heart (612±173 ml)
Mean (Gy) 44 (32.3-54.2) 33.9 (28.1-35.5) ND ND <0.001‡
V30Gy (%) 81.4 (57.4-94.7) 55.1 (42.9-63.6) 24.6 (19.7 to 29.5) <0.001⁂
V40Gy (%) 74.4 (51.6-91.3) 31.2 (21.2-36.8) 42.5 (38.1 to 47) <0.001⁂
V50Gy (%) 40.3 (13.1-71.2) 15.9 (8.4-21.7) 21.6 (14.7 to 28.5) <0.001⁂
Pericardium (179±27 ml)
Mean (Gy) 34.7 (27.2-45.4) 30.3 (24.3-36.6) 5.3 (4.3 to 6.4) <0.001⁂
V30Gy (%) 61.7 (43.8-81.2) 42.4 (30-57.9) 19.2 (16.5 to 21.9) <0.001⁂
V40Gy (%) 52.7 (38.9-72.1) 28.8 (17.7-44.8) 23.3 (21.1 to 25.4) <0.001⁂
V50Gy (%) 31.4 (15.8-43.5) 17.5 (11-29.2) 10 (7.7 to 12.3) <0.001⁂
Liver (1074±219 ml)
Mean (Gy) 11.5 (5.5-16.4) 9.6 (3.9-15.5) 0.8 (0.1 to 1.4) 0.023⁂
V30Gy (%) 14.1 (6.3-25.1) 14.1 (3.6-26.2) 0.5 (－0.5 to 1.6) 0.263⁂
Kidneys (254±52 ml)
Mean (Gy) 3.2 (0.6-11.8) 4.3 (0.4-13.7) －1 (－1.8 to －0.2) 0.017⁂
Spinal cord (57±14 ml)
Max (Gy) 44.8 (39.4-47.1) 39.7 (38.5-41) 4.7 (3.7 to 5.8) <0.001⁂
Stomach (180±60 ml)
Mean (Gy) 30.4 (10.7-45) 30.7 (10.7-42.3) 1 (－0.1 to 2.1) 0.07⁂
DVH,  dose-volume histogram; 3D-CRT,  three-dimensional conformal radiotherapy; VMAT,  volumetric modulated arc therapy; CI,  conﬁ-
dence interval; PTV,  planning target volume; Dx%,  dose received>x% of volume; VxGy,  volume receiving>x Gy; RCI; RTOG confor-
mity index; PCI,  Paddick conformity index; ND,  Not Determined.
⁂ Studentʼs paired t-test,  ‡ Wilcoxon signed-rank test
????? ?　 Late toxicities higher than grade 2
Radiation technique 3D-CRT (n＝9) IMRT/VMAT (n＝6)
Pneumonitis
Grade 2 (%) 2 (22.2) 0 (0)
Pericardial eﬀusion
Grade 2 (%) 3 (33.3) 2 (33.3)
Grade 4 (%) 1 (11.1) 0 (0)
Common Terminology Criteria for Adverse Events (CTCAE) Version 
4.0
is a risk factor for SPE.  Other studies have also reported 
the significance of the heart V30Gy for pericardial effu-
sion [29 , 35].  Interestingly,  Speirs et al.  [36] showed the 
heart dose to be an independent prognostic factor.  
There are no previous reports comparing SIB-VMAT 
and 3D-CRT for middle or lower esophageal cancer 
with ENI,  though judging from other reports 
[28 , 29 , 34-36],  the heart and pericardium V30-50Gy 
would be important parameters.  The results of our 
present investigation could lead to improved outcomes,  
because the use of SIB-VMAT can help achieve a signif-
icant reduction in the V30-50Gy for the heart and pericar-
dium.
When adopting SIB-VMAT for esophageal cancer 
with ENI,  attention should be paid to the increase in the 
low-dose area (e.g.,  V5Gy).  Nutting et al.  [37] pointed to 
a flaw in a large number of fields in the IMRT plan,  
caused by a low dose spread over the entire lungs.  
Nicolini et al.  [10] used two coplanar arcs of 360° with 
avoidance sectors to exclude direct lateral entrance 
through the lungs.  However,  these two studies were 
based on the IFI.  According to the Quantitative Analyses 
of Normal Tissue Effects in the Clinic (QUANTEC) 
[31],  it is prudent to limit the lung V20Gy to ≤ 30-35% 
and the MLD to ≤ 20-23 Gy (with conventional frac-
tionation) in order to reduce the risk of RP to ≤ 20%.
The influence of V5Gy on RP has also been reported.  
Yom et al.  [38] noted that the rate of grade 3 or higher 
RP among IMRT patients with V5Gy values exceeding 
70% was significantly larger compared to the rate 
among patients with lower V5Gy values (21% vs. 2%).  
Shaikh et al.  [39] stated that lung V5Gy was associated 
with grade 2 or higher RP in a multivariate analysis.  A 
V5Gy ≥ 65% was identified as a risk factor for the 
increased incidence of grade 2 or higher RP.  Although 
the clinical importance of the V5Gy for the lungs might 
be controversial,  a lung V5Gy < 65-70% would be a guide 
for optimization based on previous reports [38 , 39].  We 
here have shown that SIB-VMAT can meet those crite-
ria for the lungs.  In addition,  although our sample size 
was small,  the probability of late toxicities of grade 2 or 
higher RP after IMRT/VMAT was lower than that seen 
with 3D-CRT.
Locoregional failure is a serious problem in radio-
therapy for esophageal cancer [19-21].  The standard 
dose is considered to be 50.4 Gy [20].  One of the ways 
to improve the local control rate would be a dose esca-
lation to the involved tumors [22 , 23].  Shirakawa et al.  
[40] and Chang et al.  [24] reported favorable outcomes 
with high-dose (≥ 60 Gy) 3D-CRT and IMRT.  Although 
high-dose irradiation with ENI is widely used for defin-
itive treatment in Japan [16 , 18],  there are no reports 
with a dose-volume analysis of the heart and lungs 
using high-dose SIB-VMAT with ENI.  The results of 
our present study demonstrate that SIB-VMAT with 
ENI can realize dose escalation with a significant reduc-
tion in the dose delivered to the heart and pericardium 
while meeting the dose criteria for the lungs.
This study has some limitations.  First,  though the 
efficacy of the flattening filter-free (FFF) beam was 
reported [10],  we could not make a plan using these 
beams because of machine constraints.  FFF beams may 
have the potential of improving the dose distributions 
in ENI for middle or lower esophageal cancer.  Second,  
the target volume was set including the inhaled and 
exhaled positions accounting for respiratory organ 
motion,  and the relevance of respiratory gating was not 
questioned [10].  The use of respiratory gating might 
have made it possible to shrink the PTV margin and 
reduce the doses to the lung and heart.
Our study revealed that the use of SIB-VMAT can 
achieve a significant reduction in the heart and pericar-
dium doses while meeting the dose criteria for the lungs 
during the treatment of middle or lower thoracic 
esophageal cancer with ENI.  Although we need to pay 
attention to the low dose area of the lung,  our findings 
present the possibility of a new treatment strategy for 
improving the outcomes of middle or lower thoracic 
esophageal cancer.
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